Joe Rogan podcast appearance tied to rise in demand for alternative cancer treatment

Prescriptions for ivermectin plus a benzimidazole nearly doubled overall and rose 2.5x among cancer patients after Mel Gibson discussed the combination on Joe Rogan’s podcast. The study, published in JAMA Network Open, found the biggest increases among men, White patients, ages 18-64 and residents of southern states, but did not assess safety or prove causation. Researchers and clinicians warned there is no clinical evidence supporting ivermectin–benzimidazole as a cancer treatment and that celebrity endorsements can influence patient demand.

Analysis

This is less a healthcare efficacy story than a demand-shock event driven by trust transfer from a mass-media personality to an OTC-adjacent purchasing funnel. The first-order beneficiary is not a public drug company so much as retail distribution: online marketplaces, compounding-adjacent sellers, and livestock-supply channels likely absorb the volume before any regulated pharmacy data fully captures it. The second-order effect is a potential signal that misinformation can move prescription behavior even in serious disease cohorts, which raises the odds of defensive utilization of conventional oncology care and more pharmacy-level friction around off-label requests.

From a market lens, the most interesting implication is on ancillary spending rather than the drugs themselves. If patients substitute toward low-cost, non-oncology products, that does not create revenue for branded therapeutics, but it can increase physician time, prior-auth burden, and patient churn away from standard regimens — a mild negative for outpatient oncology workflow efficiency over the next 1-3 quarters. The larger economic effect may be reputational: once a celebrity-driven treatment meme takes hold, it can recur with different products, making this a template for episodic demand spikes in nutraceutical, veterinary, and e-commerce channels.

The contrarian view is that the move is probably too small to matter for public equities directly, but that is exactly why it can be misread. The underappreciated risk is not drug sales; it is data quality and patient behavior in cancer care, which can distort refill patterns, adherence, and visit cadence in ways that show up with a lag. If follow-on coverage or another celebrity amplifies the narrative, expect a second wave over the next 2-8 weeks, especially in southern and older-male cohorts where the signal appears strongest.

Key Decisions for Investors

• No direct equity trade on the headline; avoid chasing speculative long exposure in healthcare distributors or pharmacies without a clear read-through to reimbursed volume.
• Use the event as a short-term sentiment check on oncology services names (HCA, THC, DGX): if misinformation-driven substitution broadens, it modestly increases friction in standard-care utilization over 1-2 quarters; fade any strength if the group rallies on no fundamental revision.
• Long e-commerce marketplace / consumer-discretionary basket vs short regulated pharmacy basket for 2-6 weeks (e.g., AMZN vs CVS/WBA) only on confirmation of repeated search/traffic spikes; thesis is incremental share to unregulated sellers, not prescription economics.
• Monitor Google Trends, Amazon category rank, and pharmacy-fill data for ivermectin/fenbendazole proxies; if the trend persists for >10 trading days, consider a small tactical long in consumer health/OTC distribution names that benefit from panic buying, with tight stop-losses.
• Do not short oncology biotech on this headline alone; the risk-reward is poor because the article creates noise, not a durable change in tumor biology or reimbursement.